BidaskClub downgraded shares of Lantheus (NASDAQ:LNTH) from a hold rating to a sell rating in a report published on Friday, March 9th.
LNTH has been the topic of a number of other reports. Zacks Investment Research downgraded Lantheus from a hold rating to a strong sell rating in a research note on Friday, March 2nd. ValuEngine upgraded Lantheus from a hold rating to a buy rating in a research report on Saturday, February 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. Lantheus presently has a consensus rating of Hold and an average price target of $24.75.
Shares of NASDAQ:LNTH remained flat at $$15.90 during trading on Friday. The stock had a trading volume of 410,082 shares, compared to its average volume of 391,864. The firm has a market capitalization of $601.98, a price-to-earnings ratio of 15.90, a P/E/G ratio of 1.27 and a beta of 1.52. The company has a debt-to-equity ratio of 11.40, a quick ratio of 2.60 and a current ratio of 3.16. Lantheus has a 1-year low of $10.65 and a 1-year high of $24.45.
Lantheus (NASDAQ:LNTH) last released its earnings results on Monday, February 26th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.20 by ($0.08). Lantheus had a net margin of 37.23% and a negative return on equity of 68.13%. The company had revenue of $81.24 million during the quarter, compared to analyst estimates of $78.57 million. During the same period in the previous year, the firm posted $0.18 EPS. The company’s revenue for the quarter was up 9.3% on a year-over-year basis. analysts expect that Lantheus will post 1.04 earnings per share for the current fiscal year.
In related news, SVP Timothy G. Healey sold 3,696 shares of the company’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $19.58, for a total value of $72,367.68. Following the completion of the transaction, the senior vice president now directly owns 64,582 shares in the company, valued at $1,264,515.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO John W. Crowley sold 3,866 shares of the company’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $23.52, for a total value of $90,928.32. The disclosure for this sale can be found here. Insiders sold 40,709 shares of company stock worth $839,135 over the last 90 days. Company insiders own 1.20% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Cambridge Investment Research Advisors Inc. boosted its holdings in Lantheus by 13.2% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 32,861 shares of the medical equipment provider’s stock valued at $672,000 after purchasing an additional 3,841 shares during the last quarter. MetLife Investment Advisors LLC purchased a new position in Lantheus in the fourth quarter valued at about $267,000. Cornerstone Capital Management Holdings LLC. lifted its holdings in Lantheus by 95.4% during the 4th quarter. Cornerstone Capital Management Holdings LLC. now owns 186,800 shares of the medical equipment provider’s stock worth $3,819,000 after buying an additional 91,200 shares during the last quarter. Teachers Advisors LLC lifted its holdings in Lantheus by 24.8% during the 4th quarter. Teachers Advisors LLC now owns 646,336 shares of the medical equipment provider’s stock worth $13,218,000 after buying an additional 128,533 shares during the last quarter. Finally, Two Sigma Advisers LP lifted its holdings in Lantheus by 4.8% during the 4th quarter. Two Sigma Advisers LP now owns 91,400 shares of the medical equipment provider’s stock worth $1,869,000 after buying an additional 4,200 shares during the last quarter. 90.47% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Lantheus (LNTH) Stock Rating Lowered by BidaskClub” was posted by Enterprise Leader and is the sole property of of Enterprise Leader. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://theenterpriseleader.com/2018/04/02/lantheus-lnth-rating-lowered-to-sell-at-bidaskclub.html.
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.